Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model

Journal of Immunotherapy

Volumn 22, Issue 6, 1999, Pages 489-496

  Kaufman, Howard L ^a   Rao, Jay B ^a   Irivine, Kari R ^a   Bronte, Vincenzo ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Interleukin 10; Murine tumor model; Poxvirus; Recombinant vaccinia virus

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; INTERLEUKIN 10; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; FOWLPOX VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS TITRATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-10; KINETICS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0032743867     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199911000-00003     Document Type: Article

References (33)

1. Kaufman H, Kantor J, Schlom J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-7.
2. Hareuveni M, Wreschner DH, Kieny MP, et al. Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumor antigen (ETA). Vaccine 1991; 9:618-26.
3. Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995;63: 231-37.
4. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Anti-tumor activity and immune responses induced by a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine. J Natl Cancer Inst 1992;84:1084-91.
5. Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J Immunother 1997;20:48-59.
6. Bronte V, Tsung K, Rao JB, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
7. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996; 156: 3357-65.
8. de Waal Malefyt R, Yssel H, Roncarolo M, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992;4:314-20.
9. Fiorentino DF, Zlotnik A, Mossman TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
10. Fiorentino DF, Bond MW, Mossman TR. Two types of mouse helper T cell IV Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 1989;170:2081-95.
11. de Waal Malefyt R, Abrams J, Bennett B, Figdor C, de Vries J. IL-10 inhibits cytokine synthesis by human monocytes: an auto-regulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
12. Arai T, Hiromatsu K, Kobayashi N, et al. IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J Immunol 1995; 155:5743-49.
13. MacNeil IA, Suda T, Moore KW, Mossman TR, Zlotnick A. IL-10: a novel growth cofactor for mature and immature T cells. J Immunol 1990;145:4167-73.
14. Chen W, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991;147:528-34.
15. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995;154:1280-6.
16. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulated HLA class I expression. J Exp Med 1994; 180:2371-6.
17. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 1991;174:915-24.
18. Richter G, Kruger-Krasagakes S, Hein G, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993;53:4134-7.
19. Giovarelli M, Musiani P, Modesti A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995;155:3112-23.
20. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996;157:231-8.
21. Zheng LM, Ojcius DM, Garaud F, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184:579-84.
22. Wang M, Bronte V, Chen PW, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-92.
23. Davison AJ, Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res 1990;18:4285-6.
24. Smith GL, Levin JZ, Palese P, Moss B. Synthesis and cellular location of the influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology 1987;160:336-45.
25. Jenkins S, Gritz L, Fedor CH, O’Neill EM, Cohen LK, Panicali DL. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses 1991;7:991-8.
26. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175: 1423-31.
27. Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 1984;49:857-64.
28. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93:11341-48.
29. Yang G, Hellstrom KE, Mizuno MT, Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 1995;155:3897-903.
30. Rosenberg SA, Yang JC, Schwartzentruber DJ. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4: 321-6.
31. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991;174:1549-55.
32. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J Immunol 1991;146:3444-51.
33. Ding L, Linsley PS, Huang L, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151:1224-34.